All In Biotech

Drug Trial Radar · NCT06819826

A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of SC0062 Capsule in Patients with IgA Nephropathy and Proteinuria (SUCCESS-1)

Last checked: Nov 19, 2026Latest source record: Feb 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Feb 14, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2028

Sponsor

Sponsor type
Industry
First posted
Feb 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of SC0062 capsule compared to placebo in patients with IgA nephropathy in the presence of proteinuria. The participants must have a high risk of disease progression, despite of stable use of the maximum tolerated labelled or optimized dose of RAASi and/or SGLT2i for at least 12 weeks prior to randomization.

Conditions

  • IgA Nephropathy (IgAN)

Interventions

  • SC0062 strength 10mgDrug

    Subjects will take 20 mg once daily for 108 weeks during the treatment period.

  • Placebo matched to SC0062Drug

    Subjects will take 20 mg once daily for 108 weeks during the treatment period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in 24-hour urine protein-to-creatinine ratio (24h-UPCR) at 36 weeksTime frame: Baseline, 36 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial People's Hospital

    Guangzhou, Yuexiu District, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.